Mirtazapina Eg (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A, resulting in enhanced serotonergic transmission. This dual action raises both norepinephrine and serotonin levels in brain circuits that regulate mood and anxiety.

The dose of Mirtazapina Eg is individualized by the prescribing clinician based on the patient’s clinical condition, response and tolerability. The prescriber determines the appropriate strength, frequency and duration of therapy, and any adjustments are made during follow‑up visits.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mirtazapina Eg. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its combined noradrenergic and serotonergic activity and its antagonism of 5‑HT2/5‑HT3 receptors, which often leads to sedation and weight gain. While SSRIs are generally activating, mirtazapine’s profile can be advantageous for patients with insomnia or poor appetite, but individual response varies.

Mirtazapina Eg should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use.

Mirtazapina Eg is taken orally, usually with a glass of water. The tablet is swallowed whole and can be taken with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include the emergence or worsening of suicidal thoughts, especially early in treatment, agranulocytosis or severe neutropenia, significant weight gain, hepatic dysfunction, and rare hypersensitivity reactions such as severe rash or angioedema. Patients should be monitored closely for these events and seek immediate medical attention if they occur.

Mirtazapina Eg is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients. It should be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days. Caution is also advised for patients with severe hepatic impairment or uncontrolled epilepsy.